LGND
Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.
Ligand Pharmaceuticals Incorporated (LGND) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Value (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | D- (1.1) | C (2.2) | B (3.5) | B+ (3.7) | C+ (2.6) | C+ (2.6) |
| 2026-11-06 | D- (1.1) | C (2.2) | B (3.5) | B+ (3.7) | C+ (2.7) | C+ (2.6) |
| 2026-10-30 | C (2.2) | B- (2.9) | B+ (3.5) | B+ (3.7) | C+ (2.7) | B- (3.0) |
| 2026-10-23 | C (2.3) | B- (2.9) | B+ (3.5) | B (3.3) | C+ (2.6) | B- (2.9) |
| 2026-10-16 | C (2.3) | B- (2.9) | B+ (3.5) | B- (3.0) | C+ (2.6) | B- (2.9) |